TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT04910685: A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis

Sponsor: Blueprint Medicines Corporation · Phase: PHASE2/PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 534 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$10,450,032

Rescue Site Savings

+$6,885,680

Unlock Full NCT04910685 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04910685 Rescue Dossier →